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Background. Malaria in pregnancy has major impacts on mother and child health. To complement existing interventions, such 
as intermittent preventive treatment and use of impregnated bed nets, we developed a malaria vaccine candidate with the aim of re-
ducing sequestration of asexual “blood-stage” parasites in the placenta, the major virulence mechanism.
Methods. The vaccine candidate PAMVAC is based on a recombinant fragment of VAR2CSA, the Plasmodium falciparum 
protein responsible for binding to the placenta via chondroitin sulfate A (CSA). Healthy, adult malaria-naive volunteers were 
immunized with 3 intramuscular injections of 20 μg (n = 9) or 50 μg (n = 27) PAMVAC, adjuvanted with Alhydrogel or 
glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) or in a liposomal formulation with QS21 (GLA-LSQ). Allocation 
was random and double blind. The vaccine was given every 4 weeks. Volunteers were observed for 6 months following last 
immunization.
Results. All PAMVAC formulations were safe and well tolerated. A total of 262 adverse events (AEs) occurred, 94 (10 grade 2 
and 2 grade 3) at least possibly related to the vaccine. No serious AEs occurred. Distribution and severity of AEs were similar in 
all arms. PAMVAC was immunogenic in all participants. PAMVAC-specific antibody levels were highest with PAMVAC-GLA-SE. 
The antibodies inhibited binding of VAR2CSA expressing P. falciparum-infected erythrocytes to CSA in a standardized functional 
assay.
Conclusions. PAMVAC formulated with Alhydrogel or GLA-based adjuvants was safe, well tolerated, and induced functionally 
active antibodies. Next, PAMVAC will be assessed in women before first pregnancies in an endemic area.
clinical Trials Registration. EudraCT 2015-001827-21; ClinicalTrials.gov NCT02647489.
Keywords. malaria vaccine; VAR2CSA; pregnancy-associated malaria; first-in-human; phase 1 clinical trial.
The vast majority of malaria episodes occur in sub-Saharan 
Africa. With continuous exposure to the main responsible 
parasite, Plasmodium falciparum, semi-immunity develops 
over time, such that young children, especially, are at highest 
risk of developing severe malaria. During pregnancy, the pre-
viously acquired immunity is no longer sufficient, and sig-
nificant morbidity and mortality of the mother and the child 
may occur. It is estimated that pregnancy-associated malaria 
(PAM) results in 20 000 maternal and 200 000 infant deaths 
annually [1].
Plasmodium falciparum–infected red blood cells (iRBCs) 
sequester in the vasculature including the placenta [2] and 
thereby avoid removal in the spleen. Sequestration is medi-
ated by members of the P.  falciparum erythrocyte mem-
brane protein 1 (PfEMP1) family, which are expressed on 
the surface of iRBCs [3]. Each parasite genome contains ap-
proximately 60 var genes that code highly variable PfEMP1 
proteins, mediating binding to multiple different endothelial 
receptors [4]. Broadly reactive antibodies against PfEMP1 are 
acquired progressively as a result of repeated infections, pro-
tecting in concert with other immune responses first against 
severe forms of malaria and, thereafter, against uncompli-
cated infections [5–7]. One member of the PfEMP1 family, 
VAR2CSA, mediates binding to a distinct placenta-specific 
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form of chondroitin sulfate A  (CSA) [8]. Placental CSA is 
mainly attached to the proteoglycan syndecan-1 present 
in the maternal intervillous space and on the syncytiotro-
phoblast cells [9]. Thus, parasites that express VAR2CSA 
are only rarely found in nonpregnant hosts; hence, pro-
tective anti-VAR2CSA immunoglobulin G (IgG) only de-
velop during pregnancy [10] when significant exposures 
to VAR2CSA-expressing P.  falciparum occur [11, 12]. The 
level of circulating anti-VAR2CSA IgG predicts protection 
against PAM during successive pregnancies [13–17]. The 
main mechanism of protection is interference with iRBCs 
binding to placental CSA [10, 18]. In animal models, vac-
cination with recombinant subfragments of the VAR2CSA 
protein elicit binding inhibitory anti-VAR2CSA antibodies 
with characteristics similar to those acquired in pregnant 
women through natural exposure, findings that have moti-
vated the development of a vaccine [14, 19–26].
The preferred product characteristic of a placental malaria 
vaccine is induction of lifelong protection with 1 dose given 
to adolescent girls. This could be given together with the 
human papillomavirus vaccine to adolescent girls and would 
have several advantages over the World Health Organization’s 
recommended methods that consist of intermittent treat-
ment, bed nets, and prompt diagnosis. Long-lasting vaccines 
offer a much greater window of protection than any chemo-
prophylactic intervention. Vaccine-induced protection can 
be initiated before the first pregnancy, supported by bed nets 
at a critical time period because pregnancy could proceed 
unnoticed or unreported [27]. However, whether a vaccine 
will be able to stand alone remains to be tested.
Following extensive evaluation, the lead candidate 
PAMVAC was identified [20]. It spans the interdomain 
region 1 through Duffy binding-like domain 2 to interdo-
mains 2 (ID1-ID2a) of VAR2CSA. Immunization of rodents 
with PAMVAC induces adhesion-blocking antibodies with 
strain-transcending activity [20]. We used Alhydrogel as 
comparator adjuvant due to the extensive clinical experience, 
availability, and well-known safety profile. To test if anti-
body responses could be augmented and sustained, we used 
2 formulations of the Toll-like receptor 4 agonist glucopyra-
nosyl lipid adjuvant (GLA), developed and provided by the 
Infectious Disease Research Institute (IDRI; Seattle, WA). 
The first GLA formulation was a stable squalene emulsion 
(GLA-SE) and the second was a liposome formulation also 
containing QS21/saponin (GLA-LSQ).
Here, we report results of the first-in-human phase 1 clinical 
trial of 20 μg or 50 μg PAMVAC, formulated with Alhydrogel, 
GLA-SE, or GLA-LSQ in malaria-naive volunteers in Tübingen, 
Germany. Importantly, the antibodies acquired were func-
tional. The activity was influenced by formulation in particular 
GLA-SE were highly immunogenic.
METHODS
Study Design and Procedures
The study was conducted in a malaria-naive cohort in 
Tübingen, Germany. The study was done concurrently with 
a trial in Cotonou, Benin, as part of a 2-center, randomized, 
staggered, adjuvant-selection, dose-escalation clinical phase 
1 trial. Eligible volunteers were immunized with PAMVAC, 
adjuvanted with Alhydrogel, GLA-SE, or GLA-LSQ 3 times at 
4-week intervals. Vaccinations were given by intramuscular in-
jection in the deltoid. Injections were given on alternating sides, 
starting with the nondominant arm. Neither the clinical team 
nor the volunteers were aware of allocation to the Alhydrogel, 
GLA-SE, or GLA-LSQ arm. An independent pharmacist pre-
pared the syringes with masking tape. Vaccinations started in 
3 sentinel volunteers, receiving 20  μg PAMVAC adjuvanted 
with Alhydrogel, GLA-SE, or GLA-LSQ, respectively, followed 
by 2 volunteers in each group 1 day later (n = 3 per arm). At 
least 4 weeks later, the second group receiving 3 times 50  μg 
PAMVAC was started. The same procedures were applied as in 
the first group. All volunteers were examined by a physician 7 
and 28 days following each vaccination. In addition, volunteers 
were contacted actively by the clinical team 1 and 14 days fol-
lowing each vaccination. Long-term follow-up visits were per-
formed 16 and 28 weeks following the last vaccination (days 168 
and 252). All volunteers were encouraged to contact the clinical 
team in case of any adverse event (AE). During the study pe-
riod, the team was available 24 hours, 7 days a week.
The primary endpoint of the trial was the number and grade 
of AEs and serious AEs (SAEs) possibly, likely, or definitely 
related to vaccination. Severity of AEs was graded as mild (grade 
1), moderate (grade 2), severe (grade 3), or potentially life 
threatening (grade 4). For laboratory and solicited AEs, adapted 
Brighton Collaboration [28] and Food and Drug Association 
toxicity grading scales were used. The secondary endpoint was 
the PAMVAC-specific IgG concentration. Seroconversion was 
defined as reactivity above the average reactivity in plasma of 10 
unexposed individuals plus 2 standard deviations.
The trial was approved by the ethics committee of the Medical 
Faculty and the University Clinics of the University of Tübingen 
and the German Regulatory authorities. It strictly adhered to 
International Council for Technical Requirements for Human 
Use guidelines and the principles of the Declaration of Helsinki.
Vaccine
The PAMVAC vaccine candidate consists of an antigen encompass-
ing the ID1-DBL2-ID2a subunits of the FCR3 variant of VAR2CSA 
[20]. The vaccine was manufactured according to current Good 
Manufacturing Practice (cGMP) guidelines using a conventional 
batch process based on a cGMP-compliant Master Cell Bank of a 
Drosophila Schneider 2-derived cell line (Expres2ion, Denmark). 
Cells were expanded in shakers and Cultibags for 3 weeks. All 
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medium components used for the upstream process were free of 
animal components. After 3  days in the production bioreactor, 
the bulk harvest was clarified by depth filtration, and the product 
was purified by a multistep process including SP Sepharose chro-
matography, virus removal (low pH treatment), Capto Adhere 
chromatography, Sartobind Q membrane polishing, Planova 20 N 
virus removal filtration, and an ultrafiltration/diafiltration step to 
reach the final concentration of 0.4 mg/mL. The drug product was 
aseptically vialed at Miltenyi (Germany) and stored at –20°C. The 
bulk batch of Alhydrogel was produced at Brenntag (Denmark), 
diluted, and filled at Nova Laboratories (United Kingdom) under 
cGMP and stored at 2°C–8°C. GLA-SE and GLA-LSQ were man-
ufactured by the IDRI and stored at 2°C–8°C. The vaccine was 
prepared extemporaneously and passed to the clinical team in 
a syringe containing either 20 μg or 50 μg PAMVAC. The 20-μg 
PAMVAC preparations contained 0.17 mg Alhydrogel or 1 μg GLA 
with either 2% squalene (GLA-SE) or 0.4 µg QS21 (GLA-LSQ); the 
50-μg PAMVAC contained 0.43 mg Alhydrogel or 2.5 μg GLA with 
either 2% squalene or 1 µg QS21, respectively.
Immunological Investigations
Antibody Quantification
PAMVAC-specific IgG was measured by indirect enzyme-
linked immunosorbent assay (ELISA). Specific IgG present in 
the plasma bind to the ID1-ID2a coated onto the microplate 
wells and detected by horseradish peroxidase (HRP) conjugated 
goat anti-human IgG antibody. HRP activity was measured by 
color conversion of the substrate o-phenylenediamine dihydro-
chloride in the presence of hydrogen peroxide. Absorbance at 
490  nm was measured after stopping the reaction with 0.5 M 
sulfuric acid. The optical density at different plasma dilutions 
was measured with a SpectraMax plate reader using SoftMax Pro 
GxP software. The level of PAMVAC-specific plasma IgG was 
defined as the area under the curve (AUC) of the sigmoid titra-
tion curve of 11 two-fold dilutions starting from 1:100. Titration 
curves were made for each volunteer at each day of study (day 
7, 28, 35, 56, 63, 84, and 252). The binding to heterologous ID1-
ID2a variants was measured using a single dilution (1:400).
Antibody Function
The ability of immunoglobulins to interfere with the binding of 
iRBC expressing native VAR2CSA was measured as previously 
described [29]. Briefly, parasite cultures containing P.  falci-
parum ring-stage iRBC were exposed to tritium-labeled hypox-
anthine for 24 hours, after that parasites were on late-stage 
trophozoite and schizont stages. A total of 200 000 cells per well 
were incubated for 2 hours at 37°C in a 96-well plate (Falcon 
351172) coated the day before with 2 µg/mL CSA (D8428 Sigma-
Aldrich) and blocked with 1% immunoglobulin-free bovine 
serum albumin (A7030 Sigma-Aldrich). Wells were run in trip-
licate either without plasma or with 4 two-fold dilutions from 
1:10 of a pool of plasma from malaria-naive, a pool of plasma 
samples from malaria-exposed multiparous women from Benin 
[30], or test plasma in a total volume of 100 µL. Unbound iRBCs 
were washed away by a pipetting robot (Biomek 2000, Beckman 
Coulter). Subsequently, the adhering cells were harvested to a 
filter plate (Perkin-Elmer) and recorded by liquid scintillation 
counting on a Topcount NXT (Perkin-Elmer).
Statistical Analyses
Eligible participants were randomized on the day of first immu-
nization by an independent party that used a computer-gen-
erated allocation table with participant identification codes. 
Sealed envelopes were provided to the pharmacist immediately 
before vaccination. The study was an exploratory phase 1 clin-
ical trial. Hence, sample size was chosen to allow detection of 
large differences in AE pattern and PAMVAC-specific IgG con-
centration; that is, with 9 participants per group, 10% vs 80% 
of at least possibly related AEs and a difference in normally 
distributed variables larger than 60% of the standard deviation 
could be detected with 90% power and 5% alpha. Except for 
predefined immunological analyses, all statistical modeling was 
exploratory. A 2-tailed alpha <5% was considered statistically 
significant. All exploratory immunological analysis included 
dose and allocation as variables (ie, to calculate differences 
between groups) if not otherwise stated. Clinical and demo-
graphic data were captured using OpenClinica, version 3.9.1; 
calculations were done using R, version 3.4.3.
RESULTS
Study Population
The study took place between 4 May 2016 and 9 March 2017. 
In total, 36 volunteers were recruited, 9 received 20  µg and 
27 received 50  µg PAMVAC. Immunization was performed 
between 9 May 2016 and 30 August 2016. All vaccinations were 
given within the prespecified time window of 28–35 days. One 
volunteer, allocated to 50  μg PAMVAC-Alhydrogel, did not 
receive the third injection due to travel abroad. This volunteer 
remained in the study and follow-up continued until the last 
visit. One volunteer, allocated to PAMVAC-GLA-SE, missed the 
last follow-up visit (D252) because of relocation (Figure 1).
Baseline demographics were similar between the groups 
(Table 1), which represented young, malaria-naive adults, 5 
with a body mass index >30 kg/m2 (30.1, 30.5, 32.7, 36.7, and 
40.3 kg/m2) and 1 with 18.3 kg/m2.
In general, PAMVAC was well tolerated (Table 2). No SAEs 
but 262 AEs (188 grade 1, 62 grade 2, 10 grade 3, and 2 grade 
4) occurred in 36 of the 36 volunteers, 94 at least possibly re-
lated to PAMVAC (Table 2). Both grade 4 AEs were labora-
tory abnormalities observed in 1 volunteer allocated to 20  μg 
PAMVAC-Alhydrogel who presented with elevated aspartate 
aminotransferase (354 U/L) and creatinine kinase (14 000 U/L) 
concentrations without clinical symptoms or other laboratory 
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abnormalities. The laboratory values were normal at the next 
visit 17 days later and were judged unlikely related to vaccination 
(before the visit, the volunteer performed heavy-weight strength 
training after a prolonged period without exercise). Of the 10 
grade 3 AEs, 2 were at least possibly related. One volunteer (20 μg 
PAMVAC-GLA-SE) experienced an episode of fever on the day 
of first injection, another (50  μg PAMVAC-GLA-LSQ) devel-
oped grade 3 injection-site swelling (diameter, approximately 
10 cm) on the day of the third injection. Both grade 3 adverse 
reactions were transient and resolved without sequelae. AE pat-
terns were similar between the 3 adjuvants and did not increase 
in frequency or severity at booster doses (Supplementary Table 
1). Both dose levels (20 and 50 µg) were similarly well tolerated.
Immunogenicity
PAMVAC induced seroconversion in all volunteers irrespective 
of dose level and adjuvant (Figure 2). However, a significant dif-
ference in the median AUC IgG measurements was observed 
for volunteers allocated to receive PAMVAC formulated with 
GLA-based adjuvants compared to Alhydrogel. Relative to the 
Alhydrogel group, PAMVAC-IgG plasma levels 4 weeks after 
the last vaccination were highest in the GLA-SE group (6.2-fold 
higher; 95% confidence interval [CI], 3.6–10.7), followed by 
the GLA-LSQ group (4.4-fold higher; 95% CI, 2.6–7.6). This 
difference appeared more pronounced at the end of follow-up 
(day 252) with 8.5-fold (95% CI, 4.3–16.6) and 5.5 fold (95% CI, 
2.8–10.8) increases in the GLA-SE and GLA-LSQ compared to 
the Alhydrogel group, respectively. However, in all groups, the 
plasma levels decreased from day 84 to day 252 with no signifi-
cant effect of allocation and dose.
Time to peak PAMVAC-IgG concentration was shorter in 
volunteers vaccinated with PAMVAC-GLA-SE (9 days earlier; 
95% CI, 1–17) and PAMVAC-GLA-LSQ (12 days earlier; 95% 
CI, 4–20) compared to PAMVAC-Alhydrogel. A  comparison 
of peak concentrations instead of total PAMVAC-IgG at 4 
weeks following last immunization (day 84)  showed a similar 
fold difference in concentration of GLA-based compared to 
Alhydrogel-based adjuvants.
The functional response that protects against placental malaria 
may include many effector mechanisms. However, an antibody 
response that hinders iRBC sequestering, thereby alleviating 
detrimental downstream inflammation events that take place in 
the placenta, appears the most plausible and well-documented 
mechanism of protection [31–33]. Our binding inhibition assay 
Figure 1. Study flow chart. Abbreviations: GLA-LSQ, glucopyranosyl lipid adjuvant containing QS21/saponin; GLA-SE, glucopyranosyl lipid adjuvant in stable emulsion; 
PAMVAC, pregnancy-associated malaria vaccine.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/69/9/1509/5281109 by D
anish R
egions user on 29 April 2020
Phase 1 Clinical Trial of a PAM Vaccine • cid 2019:69 (1 November) • 1513
measures the ability of in vitro cultured VAR2CSA-expressing 
iRBC to bind to the placental receptor CSA coated to a 96-well plate 
in the presence of plasma IgG [29, 34]. Four weeks following the 
last immunization, binding inhibition at a 1:20 dilution of plasma 
was significantly higher in volunteers vaccinated with GLA-SE 
(23% difference to Alhydrogel; 95% CI, 7–40) compared to GLA-
LSQ and Alhydrogel formulated PAMVAC (Figure 3). This differ-
ence was not significant at 1:10 dilution (Supplementary Figure 
S1). The overall level of antibodies against PAMVAC measured by 
ELISA was correlated linearly with the level of binding inhibition 
at 1:20 dilution (P = .0005; Supplementary Figure S2). In contrast, 
the level of functional antibodies was significantly higher in mice 
when the PAMVAC antigen was formulated with GLA-LSQ than 
in GLA-SE or Alhydrogel (Supplementary Figure S3).
Due to substantial sequence variability even in the mini-
mal binding domain of VAR2CSA, we investigated the level of 
cross-reactivity of PAMVAC-induced antibodies on day 84 by 
ELISA. We found that immunized volunteers acquired substan-
tial levels of antibodies with specificity for the PAMVAC region 
of genetic variants representing different clades of VAR2CSA 
(Figure 4). The highest level of correlation was in PAMVAC-
GLA-SE vaccinated volunteers with a pattern that represented 
genetic distance (ie, the Plasmodium reichenowi variant being 
least similar to the vaccine antigen; Supplementary Figure 4).
DISCUSSION
To our knowledge, this is the first report of a clinical trial testing 
a vaccine to generate an antibody response against the molecular 
determinants of a virulence factor of P.  falciparum malaria. The 
vaccine was well tolerated with only 2 transient and at least pos-
sibly related grade 3 AEs. One volunteer experienced an episode of 
fever on the day of first injection, and another developed an injec-
tion-site swelling. In contrast to preclinical findings in rodents and 
rabbits demonstrating induction of high levels of antibodies using 
GLA-LSQ compared to Alhydrogel or GLA-SE (see Supplementary 
Figure 4), we found that PAMVAC formulated with GLA-LSQ did 
not improve immunogenicity compared to GLA-SE. Peak response 
and time to peak were superior to the Alhydrogel formulation 
with both GLA-based formulations. Interestingly, the plasma of 
GLA-SE–vaccinated volunteers had the highest binding-inhibitory 
capacity. We observed substantial binding of IgG to heterologous 
PAMVAC recombinant proteins, even as diverse as the VAR2CSA 
variant from the P. reichenowi genome. Again, the GLA-SE formu-
lation showed the highest cross-reactivity.
Currently, there is no valid surrogate measure for protection 
against placental malaria [35]. Validation of such a surrogate 
will need a large trial powered to measure efficacy. Nevertheless, 
naturally acquired protection is correlated with both high levels 
of IgG against VAR2CSA per se and IgG that targets epitopes 
involved in binding to CSA and therefore qualify as plausible 
candidates. Is it possible to assess whether antibody responses 
such as those acquired during first pregnancy by women living 
in areas of high malaria endemicity are functionally equiv-
alent to vaccine-induced ones? Antibodies acquired during 
first pregnancy may result from repeated infections during 
pregnancy or even a single mosquito inoculating several dif-
ferent parasites. This complexity impedes the identification of 
structural features or feature patterns that define a protective 
response, as naturally acquired antibodies may be both re-
dundant and targeting nonprotecting epitopes. The PAMVAC 
antigen can induce cross-reactive binding-inhibitory antibod-
ies in rodents at a level similar to that found in hyperimmune 
Table 2. Related Adverse Events
Severity 20/Al (n = 3)a 20/GLA-LSQ (n = 3)a 20/GLA-SE (n = 3)a 50/Al (n = 9)a 50/GLA-LSQ (n = 9)a 50/GLA-SE (n = 9)a
1 8 (3) 7 (2) 7 (3) 17 (8) 24 (7) 19 (7)
2 1 (1) 0 0 1 (1) 2 (1) 6 (4)
3 0 0 1 (1) 0 1 (1) 0
Abbreviations: GLA-LSQ, glucopyranosyl lipid adjuvant containing QS21/saponin; GLA-SE, glucopyranosyl lipid adjuvant in stable emulsion. 
aNumber of adverse events (number of volunteers).
Table 1. Baseline Demographics of the Study Volunteers
 Age, ya Sexb Weight, kga Body Mass Index,a kg/m2
20/Al 23.9 (21.3; 32.3) 1:2 69 (51; 81) 22.3 (18.7; 25.6)
20/GLA-SE 27.9 (23.2; 29.3) 2:1 81 (71; 82) 28.7 (22.7; 30.5)
20/GLA-LSQ 20.4 (19.4; 23.4) 3:0 64 (62; 79) 20.9 (18.3; 28.0)
50/Al 24.2 (19.9; 35.3) 6:3 74 (53; 107) 22.8 (19.7; 40.3)
50/GLA-SE 25.3 (20.8; 33.3) 2:7 82 (59; 138) 25.3 (21.0; 36.7)
50/GLA-LSQ 22.8 (18.3; 36.4) 6:3 80 (53; 92) 25.7 (19.5; 32.7)
Abbreviations: GLA-LSQ, glucopyranosyl lipid adjuvant containing QS21/saponin; GLA-SE, glucopyranosyl lipid adjuvant in stable emulsion. 
aMedian (min; max).
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women [20]. In German malaria-naive individuals, it appears 
that vaccine-induced IgG targets both conserved epitopes and 
epitopes involved with specific binding to CSA, but at a lower 
level than observed during both preclinical investigations and 
in multiparous women living in endemic areas. However, it is 
not clear how this property translates into protective efficacy of 
a VAR2CSA-based vaccine.
Previous phase 1 studies with malaria vaccines have shown 
that immune responses can be significantly lower in endemic 
populations, but it is also conceivable that vaccine responses 
Figure 3. Functional activity of induced antibodies. The binding inhibitory activity of plasma against erythrocytes infected with VAR2CSA expressing FCR3 parasites binding 
to chondroitin sulfate A (CSA). Samples from individuals enrolled in the study, a pool of plasma from naive Danes, and a pool of plasma from multiparous women living in a 
highly endemic area in Benin. The plasma was tested at day -1 at a dilution of 1:10 and at day 84 at a 1:20 dilution. Briefly, CSA was coated at the bottom of 96 well plates. 
Infected erythrocytes were added along with plasma. The plates were washed using a washing robot (Biomek 2000). Values shown are the percentage inhibition according to 
binding in wells without plasma after subtraction of background binding values in wells without CSA. The upper and lower horizontal lines indicate the positive and negative 
control plasma samples. All samples were run in triplicate. The 50-µg group is indicated by triangles; 20-µg group is indicated by circles. See also Supplementary Figure S2. 
Abbreviations: GLA-LSQ, glucopyranosyl lipid adjuvant containing QS21/saponin; GLA-SE, glucopyranosyl lipid adjuvant in stable emulsion.
Figure 2. Pregnancy-associated malaria vaccine (PAMVAC) immunoglobulin G (IgG) over time. Enzyme-linked immunosorbent assay was used to measure IgG antibody 
reactivity generated against PAMVAC. The y-axis shows the area under the curve (AUC) calculated for each individual at day 7, 28, 35, 56, 63, 84, and 252. The AUC unit 
was derived from recording the optical density values in plasma after 11 two-fold dilutions (from 1/100 to 1/102 400), yielding a titration curve under which the area was 
calculated. Shown are the AUC values for individuals who received the 20-µg dose (upper panel) and 50-µg dose (lower panel) according to adjuvant and days after first 
vaccination. Each individual was vaccinated at time 0, 28, and 56 days (vertical dotted lines). Abbreviations: GLA-LSQ, glucopyranosyl lipid adjuvant containing QS21/saponin; 
GLA-SE, glucopyranosyl lipid adjuvant in stable emulsion.
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may be augmented by previous exposure [36, 37]. These ques-
tions will be addressed in measurements of IgG longevity and 
cross-reactivity of PAMVAC-vaccinated nulligravid women in 
Benin. Also, studies on the specific amino acids targeted are 
ongoing to elucidate whether structural modifications can be 
made in order to generate a more potent second-generation 
PAMVAC capsid-like particle vaccine [38, 39].
In conclusion, PAMVAC formulated with Alhydrogel, 
GLA-SE, or GLA-LSQ is well tolerated in healthy, malaria-na-
ive adults. The antigen induces a functional IgG response and is 
most immunogenic when formulated with GLA-SE.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
Notes
Acknowledgments. The authors thank the team of the Clinical Trial 
Platform at the Institute of Tropical Medicine of the University of Tübingen 
and the German Center for Infection Research for generous support and 
help. They thank Anne Corfitz for technical assistance with parasite cultures 
and binding assays; Bezim Berisha and Elham Alijazaeri for technical assis-
tance with protein expression and purification; Nahla Chehabi for technical 
assistance with DNA cloning; and Nicola Stingelin for ethical reviews.
Financial support. This work was supported by the European Union in 
the Seventh Framework Programme (FP7-HEALTH-2012-INNOVATION; 
under grant agreement 304815), the Danish Advanced Technology Foundation 
(under grant number 005-2011-1), and a Medium Scale Collaborative Project 
supported by the German Federal Ministry of Education and Research 
(Bundesministerium für Bildung und Forschung) through EVI, KfW, and 
Irish Aid. This work was supported in part by the Bill and Melinda Gates 
Foundation (grant numbers 42387 and OPP1055855 to S. G. R.).
Potential conflicts of interest. W. A. d.  J.  and C. D. have a patent is-
sued on the S2 Expression platform (PCT/EP2009/057278). L. P., W. A. J., 
C.  D., and M.  aS.  were employed by ExpreS2ion Biotechnologies during 
the study. T.  G. T.  and A.  S.  have a patent issued on VAR2CSA vaccines 
(PCT/DK2003/000938). T.  G. T., A.  S., and M.  A. N.  appear on a patent 
issued on virus like particle vaccines (US10086056B2) and are co-owners 
and founders of Nextgen Vaccines and AdaptVac that develops VLP vac-
cines. M.  E.  reports grants from GSK, DFG, EDCTP, BMBF, and Takeda 
outside the submitted work. All other authors report no potential conflicts. 
All authors have submitted the ICMJE Form for Disclosure of Potential 
Conflicts of Interest. Conflicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Moore KA, Simpson JA, Scoullar MJL, McGready R, Fowkes FJI. Quantification 
of the association between malaria in pregnancy and stillbirth: a systematic 
review and meta-analysis. Lancet Glob Health 2017; 5:e1101–12.
2. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. 
Nature 2002; 415:673–9.
3. Baruch DI, Pasloske BL, Singh HB, et al. Cloning the P. falciparum gene encoding 
PfEMP1, a malarial variant antigen and adherence receptor on the surface of par-
asitized human erythrocytes. Cell 1995; 82:77–87.
4. Su  XZ, Heatwole  VM, Wertheimer  SP, et  al. The large diverse gene family 
var encodes proteins involved in cytoadherence and antigenic variation of 
Plasmodium falciparum-infected erythrocytes. Cell 1995; 82:89–100.
5. Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K. Parasite anti-
gens on the infected red cell surface are targets for naturally acquired immunity 
to malaria. Nat Med 1998; 4:358–60.
6. Nielsen MA, Staalsoe T, Kurtzhals JA, et al. Plasmodium falciparum variant sur-
face antigen expression varies between isolates causing severe and nonsevere 
malaria and is modified by acquired immunity. J Immunol 2002; 168:3444–50.
7. Marsh K, Howard RJ. Antigens induced on erythrocytes by P. falciparum: expres-
sion of diverse and conserved determinants. Science 1986; 231:150–3.
8. Salanti A, Staalsoe T, Lavstsen T, et al. Selective upregulation of a single distinctly 
structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum 
involved in pregnancy-associated malaria. Mol Microbiol 2003; 49:179–91.
9. Ayres PM, Mandel CT, Pehrson C, et al. Placental sequestration of Plasmodium 
falciparum malaria parasites is mediated by the interaction between VAR2CSA 
and chondroitin sulfate A on Syndecan-1. PLoS Pathog 2016; 12:e1005831.
10. Fried M, Nosten F, Brockman A, Brabin BJ, Duffy PE. Maternal antibodies block 
malaria. Nature 1998; 395:851–2.
11. Ricke CH, Staalsoe T, Koram K, et al. Plasma antibodies from malaria-exposed 
pregnant women recognize variant surface antigens on Plasmodium falci-
parum-infected erythrocytes in a parity-dependent manner and block parasite 
adhesion to chondroitin sulfate A. J Immunol 2000; 165:3309–16.
12. Salanti A, Dahlbäck M, Turner L, et al. Evidence for the involvement of VAR2CSA 
in pregnancy-associated malaria. J Exp Med 2004; 200:1197–203.
13. Tuikue Ndam NG, Salanti A, Le-Hesran  JY, et  al. Dynamics of anti-VAR2CSA 
immunoglobulin G response in a cohort of Senegalese pregnant women. J Infect 
Dis 2006; 193:713–20.
14. Brolin  KJ, Persson  KE, Wahlgren  M, Rogerson  SJ, Chen  Q. Differential recog-
nition of P.  falciparum VAR2CSA domains by naturally acquired antibodies in 
pregnant women from a malaria endemic area. PLoS One 2010; 5:e9230.
15. Tutterrow  YL, Salanti  A, Avril  M, et  al. High avidity antibodies to full-length 
VAR2CSA correlate with absence of placental malaria. PLoS One 2012; 7:e40049.
16. Mayor A, Kumar U, Bardají A, et al. Improved pregnancy outcomes in women 
exposed to malaria with high antibody levels against Plasmodium falciparum. J 
Infect Dis 2013; 207:1664–74.
Figure 4. Correlation matrix of immunoglobulin G (IgG) reactivity between VAR2CSA variants. Alhydrogel (A), glucopyranosyl lipid adjuvant containing QS21/saponin (B), 
and glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) (C). The shading is proportional to the level of cross-reactivity measured by correlating the reactivity of IgG in 
plasma from individuals in each arm of the study. Numbers indicated according to the shading are r2-values, denoting how close the data are to the fitted regression line. 
Note the overall higher correlation in the GLA-SE adjuvanted group. See also Supplementary Figure S4.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/69/9/1509/5281109 by D
anish R
egions user on 29 April 2020
1516 • cid 2019:69 (1 November) • Mordmüller et al
17. Ndam NT, Denoeud-Ndam L, Doritchamou J, et al. Protective antibodies against 
placental malaria and poor outcomes during pregnancy, Benin. Emerg Infect Dis 
2015; 21:813–23.
18. Duffy PE, Fried M. Antibodies that inhibit Plasmodium falciparum adhesion to 
chondroitin sulfate A are associated with increased birth weight and the gesta-
tional age of newborns. Infect Immun 2003; 71:6620–3.
19. Dechavanne  S, Srivastava  A, Gangnard  S, et  al. Parity-dependent recognition 
of DBL1X-3X suggests an important role of the VAR2CSA high-affinity CSA-
binding region in the development of the humoral response against placental ma-
laria. Infect Immun 2015; 83:2466–74.
20. Nielsen MA, Resende M, de Jongh WA, et al. The influence of sub-unit compo-
sition and expression system on the functional antibody response in the devel-
opment of a VAR2CSA based Plasmodium falciparum placental malaria vaccine. 
PLoS One 2015; 10:e0135406.
21. Pinto  VV, Ditlev  SB, Jensen  KE, et  al. Differential induction of functional IgG 
using the Plasmodium falciparum placental malaria vaccine candidate VAR2CSA. 
PLoS One 2011; 6:e17942.
22. Barfod  L, Dobrilovic  T, Magistrado  P, et  al. Chondroitin sulfate A-adhering 
Plasmodium falciparum-infected erythrocytes express functionally important an-
tibody epitopes shared by multiple variants. J Immunol 2010; 185:7553–61.
23. Doritchamou J, Bigey P, Nielsen MA, et al. Differential adhesion-inhibitory pat-
terns of antibodies raised against two major variants of the NTS-DBL2X region of 
VAR2CSA. Vaccine 2013; 31:4516–22.
24. Doritchamou J, Sabbagh A, Jespersen JS, et al. Identification of a major dimorphic 
region in the functionally critical N-terminal ID1 domain of VAR2CSA. PLoS 
One 2015; 10:e0137695.
25. Fernandez P, Petres S, Mécheri S, Gysin J, Scherf A. Strain-transcendent immune 
response to recombinant Var2CSA DBL5-ε domain block P. falciparum adhesion 
to placenta-derived BeWo cells under flow conditions. PLoS One 2010; 5:e12558.
26. Fried  M, Avril  M, Chaturvedi  R, et  al. Multilaboratory approach to preclinical 
evaluation of vaccine immunogens for placental malaria. Infect Immun 2013; 
81:487–95.
27. Schmiegelow C, Matondo S, Minja DTR, et al. Plasmodium falciparum infection 
early in pregnancy has profound consequences for fetal growth. J Infect Dis 2017; 
216:1601–10.
28. Bonhoeffer  J, Imoukhuede  EB, Aldrovandi  G, et  al; Brighton Collaboration 
Clinical Trial Protocol Working Group. Template protocol for clinical trials inves-
tigating vaccines–focus on safety elements. Vaccine 2013; 31:5602–20.
29. Nielsen  MA, Salanti  A. High-throughput testing of antibody-dependent 
binding inhibition of placental malaria parasites. Methods Mol Biol 2015; 
1325:241–53.
30. Gbédandé K, Fievet N, Viwami F, et al; Multi-centre research paper. Clinical de-
velopment of a VAR2CSA-based placental malaria vaccine PAMVAC: quantifying 
vaccine antigen-specific memory B & T cell activity in Beninese primigravidae. 
Vaccine 2017; 35:3474–81.
31. Hviid L, Salanti A. VAR2CSA and protective immunity against pregnancy-associ-
ated Plasmodium falciparum malaria. Parasitology 2007; 134:1871–6.
32. Rogerson SJ, Hviid L, Duffy PE, Leke RF, Taylor DW. Malaria in pregnancy: path-
ogenesis and immunity. Lancet Infect Dis 2007; 7:105–17.
33. Tuikue-Ndam N, Deloron P. Developing vaccines to prevent malaria in pregnant 
women. Expert Opin Biol Ther 2015; 15:1173–82.
34. Pehrson C, Heno KK, Adams Y, et al. Comparison of functional assays used in the 
clinical development of a placental malaria vaccine. Vaccine 2017; 35:610–8.
35. McCall MBB, Kremsner PG, Mordmüller B. Correlating efficacy and immunoge-
nicity in malaria vaccine trials. Semin Immunol 2018; 39:52–64.
36. Cockburn  IA, Seder  RA. Malaria prevention: from immunological concepts to 
effective vaccines and protective antibodies. Nat Immunol 2018; 19:1199–211.
37. Draper SJ, Angov E, Horii T, et al. Recent advances in recombinant protein-based 
malaria vaccines. Vaccine 2015; 33:7433–43.
38. Palladini  A, Thrane  S, Janitzek  CM, et  al. Virus-like particle display of HER2 
induces potent anti-cancer responses. Oncoimmunology 2018; 7:e1408749.
39. Thrane S, Janitzek CM, Matondo S, et al. Bacterial superglue enables easy devel-
opment of efficient virus-like particle based vaccines. J Nanobiotechnology 2016; 
14:30.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/69/9/1509/5281109 by D
anish R
egions user on 29 April 2020
